223 related articles for article (PubMed ID: 24628238)
1. Combining anti-tumor alkyl-phospholipid analogs and radiotherapy: rationale and clinical outlook.
Verheij M; Moolenaar WH; Blitterswijk WJ
Anticancer Agents Med Chem; 2014 May; 14(4):618-28. PubMed ID: 24628238
[TBL] [Abstract][Full Text] [Related]
2. Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy.
Vink SR; van Blitterswijk WJ; Schellens JH; Verheij M
Cancer Treat Rev; 2007 Apr; 33(2):191-202. PubMed ID: 17287087
[TBL] [Abstract][Full Text] [Related]
3. Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects.
van Blitterswijk WJ; Verheij M
Curr Pharm Des; 2008; 14(21):2061-74. PubMed ID: 18691116
[TBL] [Abstract][Full Text] [Related]
4. Anticancer mechanisms and clinical application of alkylphospholipids.
van Blitterswijk WJ; Verheij M
Biochim Biophys Acta; 2013 Mar; 1831(3):663-74. PubMed ID: 23137567
[TBL] [Abstract][Full Text] [Related]
5. Cancer Radiosensitizers.
Wang H; Mu X; He H; Zhang XD
Trends Pharmacol Sci; 2018 Jan; 39(1):24-48. PubMed ID: 29224916
[TBL] [Abstract][Full Text] [Related]
6. Signal transduction inhibitors as radiosensitizers.
Tenzer A; Zingg D; Riesterer O; Vuong V; Bodis S; Pruschy M
Curr Med Chem Anticancer Agents; 2002 Nov; 2(6):727-42. PubMed ID: 12678723
[TBL] [Abstract][Full Text] [Related]
7. Novel therapeutics in combination with radiotherapy to improve cancer treatment: rationale, mechanisms of action and clinical perspective.
Verheij M; Vens C; van Triest B
Drug Resist Updat; 2010; 13(1-2):29-43. PubMed ID: 20167530
[TBL] [Abstract][Full Text] [Related]
8. [Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].
Azria D; Larbouret C; Robert B; Culine S; Ychou M; Verrelle P; Dubois JB; Pèlegrin A
Bull Cancer; 2003 Nov; 90 Spec No():S202-12. PubMed ID: 14763141
[TBL] [Abstract][Full Text] [Related]
9. The paradox of histone deacetylase inhibitor-mediated modulation of cellular responses to radiation.
Karagiannis TC; El-Osta A
Cell Cycle; 2006 Feb; 5(3):288-95. PubMed ID: 16418577
[TBL] [Abstract][Full Text] [Related]
10. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?
Choy H; Milas L
J Natl Cancer Inst; 2003 Oct; 95(19):1440-52. PubMed ID: 14519750
[TBL] [Abstract][Full Text] [Related]
11. Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents.
Zerp SF; Vink SR; Ruiter GA; Koolwijk P; Peters E; van der Luit AH; de Jong D; Budde M; Bartelink H; van Blitterswijk WJ; Verheij M
Anticancer Drugs; 2008 Jan; 19(1):65-75. PubMed ID: 18043131
[TBL] [Abstract][Full Text] [Related]
12. Novel targeted radiosensitisers in cancer treatment.
Zaidi SH; Huddart RA; Harrington KJ
Curr Drug Discov Technol; 2009 Jun; 6(2):103-34. PubMed ID: 19519337
[TBL] [Abstract][Full Text] [Related]
13. Glycosidated phospholipids - a promising group of anti-tumour lipids.
Semini G; Hildmann A; von Haefen C; Danker K
Anticancer Agents Med Chem; 2014 May; 14(4):607-17. PubMed ID: 24628240
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of disease: Radiosensitization by epidermal growth factor receptor inhibitors.
Sartor CI
Nat Clin Pract Oncol; 2004 Dec; 1(2):80-7. PubMed ID: 16264825
[TBL] [Abstract][Full Text] [Related]
15. New radiosensitizing regimens, drugs, prodrugs, and candidates.
Vallerga AK; Zarling DA; Kinsella TJ
Clin Adv Hematol Oncol; 2004 Dec; 2(12):793-805. PubMed ID: 16166960
[TBL] [Abstract][Full Text] [Related]
16. Radiation-induced apoptosis in tumors: effect of radiation modulating agents.
Milas L; Gregoire V; Hunter N; Kurdoglu B; Mason K; Meyn R
Adv Exp Med Biol; 1997; 400B():559-64. PubMed ID: 9547604
[No Abstract] [Full Text] [Related]
17. Anti-tumor activities of lipids and lipid analogues and their development as potential anticancer drugs.
Murray M; Hraiki A; Bebawy M; Pazderka C; Rawling T
Pharmacol Ther; 2015 Jun; 150():109-28. PubMed ID: 25603423
[TBL] [Abstract][Full Text] [Related]
18. Hypoxic radiosensitizers and hypoxic cytotoxins in radiation oncology.
Weinmann M; Welz S; Bamberg M
Curr Med Chem Anticancer Agents; 2003 Sep; 3(5):364-74. PubMed ID: 12871083
[TBL] [Abstract][Full Text] [Related]
19. Membrane targeted anticancer drugs: potent inducers of apoptosis and putative radiosensitisers.
Jendrossek V; Handrick R
Curr Med Chem Anticancer Agents; 2003 Sep; 3(5):343-53. PubMed ID: 12871080
[TBL] [Abstract][Full Text] [Related]
20. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors.
Khuntia D; Mehta M
Expert Rev Anticancer Ther; 2004 Dec; 4(6):981-9. PubMed ID: 15606327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
